Core Points - Beijing Kexing Holdings (Kexing) signed two Product Development Partnership (PDP) projects with the Brazilian Ministry of Health on November 24, 2025, becoming the first Chinese vaccine company to win such contracts [1] - Kexing will collaborate with local partners Tecpar Institute and Eurofarma to establish a vaccine industry platform in Brazil, aiming to enhance local vaccine production capacity and provide approximately 60 million doses of varicella and rabies vaccines over the next decade, valued at over $700 million [1] - The signing ceremony took place at the Albert Einstein Hospital in São Paulo, with Kexing's Vice President Meng Weining emphasizing the company's commitment to building a robust public health system and meeting Brazil's national needs through reliable technology and long-term cooperation [1] Industry Insights - The PDP project aims to strengthen public health systems by ensuring stable supply of essential medicines through a full lifecycle production strategy [2] - The core of the PDP initiative is to build local production capabilities in Brazil by partnering with international pharmaceutical companies that possess advanced technologies, ultimately achieving self-sufficiency in critical medications [2]